Alexander Baraniskin1, Jean-Luc Van Laethem2, Lucjan Wyrwicz3, Ulrich Guller4, Harpreet S Wasan5, Tamara Matysiak-Budnik6, Thomas Gruenberger7, Michel Ducreux8, Fatima Carneiro9, Eric Van Cutsem10, Thomas Seufferlein11, Wolff Schmiegel12. 1. Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany. Electronic address: Alexander.Baraniskin@rub.de. 2. Department of Gastroenterology and Digestive Oncology, Hopitaux Universitaires Bordet-Erasme, Brussels, Belgium. 3. Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. 4. Division of Medical Oncology & Hematology, Kantonsspital, St. Gallen, Switzerland. 5. Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK. 6. Hepato-Gastroenterology Department, Institut des Maladies de L'Appareil Digestif, Nantes University Hospital, Nantes, France. 7. Department of Surgery I, Rudolfstiftung Hospital, Vienna, Austria. 8. Department of Medical Oncology, Gustave Roussy, Villejuif and Université Paris-Saclay, Saint Aubain, France. 9. Faculty of Medicine of the University of Porto (FMUP), Centro Hospitalar de São João (CHSJ) and Ipatimup/i3S, Porto, Portugal. 10. Digestive Oncology, University Hospitals and KU Leuven, Leuven, Belgium. 11. Department of Internal Medicine I, University of Ulm, Ulm, Germany. 12. Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Abstract
BACKGROUND AND SCOPE: In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the clinical routine use. METHODOLOGY: Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both clinical expertise and updated evidence-based medicine. RESULTS: Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for clinical routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made. CONCLUSION: The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily clinical practice.
BACKGROUND AND SCOPE: In the epoch of precision medicine and personalised oncology, which aims to deliver the right treatment to the right patient, molecular genetic biomarkers are a topic of growing interest. The aim of this expert discussion and position paper is to review the current status of various molecular tests for gastrointestinal (GI) cancers and especially considering their significance for the clinical routine use. METHODOLOGY: Opinion leaders and experts from diverse nationalities selected on scientific merit were asked to answer to a prepared set of questions about the current status of molecular diagnostics in different GI cancers. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both clinical expertise and updated evidence-based medicine. RESULTS: Preselected molecular genetic biomarkers that are described and disputed in the current medical literature in different GI cancers were debated, and recommendations for clinical routine practice were made whenever possible. Furthermore, the preanalytical variations were commented and proposals for quality controls of biospecimens were made. CONCLUSION: The current article summarises the recommendations of the expert committee regarding prognostic and predictive molecular genetic biomarkers in different entities of GI cancers. The briefly and comprehensively formulated guidelines should assist clinicians in the process of decision making in daily clinical practice.
Authors: Irene Gullo; Patrícia Oliveira; Maria Athelogou; Gilza Gonçalves; Marta L Pinto; Joana Carvalho; Ana Valente; Hugo Pinheiro; Sara Andrade; Gabriela M Almeida; Ralf Huss; Kakoli Das; Patrick Tan; José C Machado; Carla Oliveira; Fátima Carneiro Journal: Gastric Cancer Date: 2018-05-19 Impact factor: 7.370